Research Projects

This database contains information on EU funded dementia research projects, undertaken since 2007. It is the product of a mapping exercise of European funding programmes for dementia research conducted by Alzheimer Europe in 2020. This database is not an exhaustive resource of information. It contains information about European projects that are funded by European programmes including FP7, H2020, IMI, JNPD, AAL and EU Health.

Filters

(Clear all)

40 Hz Masked Light: A new venture to slow the progression of Alzheimer’s Disease

BRIGHT

While Alzheimer’s Disease (AD) is a global pandemic, it has been estimated that a five-year delay in the disease onset could reduce the disease prevalence – and its costs – by up to 33% over the next decades, representing potential savings over €100bn in EU alone. However, there are still significant roadblocks ahead as current drugs do not untap...

Funding Programme
Start Date
End Date
Total Funding
€ 71 429
European Countries Involved

Alzheimer's Disease (AD) Detect & Prevent - Presymptomatic AD detection and prevention

AD Detect-Prevent

Alzheimer’s disease (AD) is central to the rapidly growing and crushing ageing challenge that threatens to economically undermine today’s health care system. AD prevalence will grow to over 100m cases in 2050. AD is incurable, but can be prevented. Detecting pre-symptomatic signs of AD in at-risk groups and intervening early may be the only viable...
Funding Programme
Start Date
End Date
Total Funding
€ 3 880 990
European Countries Involved

Biomarkers for Alzheimer’s disease and Parkinson’s disease.

BIOMARKAPD

Neurodegenerative disorders, represented mostly by Alzheimer's disease (AD) and Parkinson's disease (PD), are characterised by progressive neuronal impairment and death. In spite of the brain's known capacity for regeneration, lost neurons generally cannot be replaced. Therefore, drugs aimed at inhibiting neurodegenerative processes are likely to...

Funding Programme
Start Date
End Date
Total Funding
€ 449 066

Blood Biomarker-based Diagnostic Tools for Early Stage Alzheimer’s Disease

BBDiag

Alzheimer’s disease (AD) affects more than 7 million people in Europe and this figure is expected to double every 20 years. Despite intensive efforts, no disease-modifying treatments or preventive strategies are available. The lack of specific, sensitive and minimally invasive diagnostics to identify people with early-stage AD to be included in...

Funding Programme
Start Date
End Date
Total Funding
€ 3 465 708
European Countries Involved

Calcium-Sensing Receptor (CaSR): Therapeutics for Non-Communicable Diseases

CaSR Biomedicine

The calcium sensing receptor (CaSR) is a class C Gprotein-coupled receptor that plays a pivotal role in systemic calcium metabolism by regulating parathyroid hormone secretion and urinary Ca excretion. Abnormal CaSR function is implicated in calciotropic disorders, and in non-calciotropic disorders such as Alzheimer’s disease (AD), cardiovascular...
Funding Programme
Start Date
End Date
Total Funding
€ 3 657 195

Consortium on Health and Ageing: Network of Cohorts in Europe and the United States

CHANCES

CHANCES aims at combining and integrating on-going cohort studies in order to produce evidence on ageing-related health characteristics and determinants in Europe, and their socio-economic implications. 15 cohorts participate, covering populations from 18 EU Member States, 4 associate countries, and 3 additional countries. The combination of these...

Funding Programme
Start Date
End Date
Total Funding
€ 15 410 903

Deciphering Interactions of Acquired Risk Factors and ApoE-mediated Pathways in Alzheimer’s Disease

DACAPO-AD

Alzheimer’s disease (AD) imposes an enormous personal burden on patients and caregivers, as well as a tremendous socio-economic impact on society. However, there is a paucity of pharmaceutical or interventional strategies that have a proven impact on the incidence or progression of AD. One reason is that most models are based on familial (early...
Funding Programme
Start Date
End Date
Total Funding
€ 1 594 408
European Countries Involved

Developing new therapies for Batten disease

BATCure

The goal of BATCure is to advance the development of new therapeutic options for a group of rare lysosomal diseases - neuronal ceroid lipofuscinoses (NCL) or Batten disease. There are > thousand affected across Europe, with a combined incidence of c.1:100 000. The NCLs are devastating and debilitating genetic disorders that mainly affect children...
Funding Programme
Start Date
End Date
Total Funding
€ 6 000 681
European Countries Involved

Development of a novel FGL therapy and translational tests for regenerative treatment of neurological disorders

NEUROFGL

Neurodegenerative disorders such as, Alzheimer’s disease (AD), Mild Cognitive Impairment (MCI), stroke, Traumatic Brain Injury (TBI) and chronic stress create a major economic burden to society and a substantial reduction in quality of life for patients and families. The development of neuroregenerative therapies is notoriously difficult and...

Funding Programme
Start Date
End Date
Total Funding
€ 7 807 910
European Countries Involved

European Bank for induced pluripotent Stem Cells

EBiSC

Induced pluripotent stem cells (iPSC) are the cornerstone of many regenerative medicine projects, and offer researchers a powerful new approach to model and study a range of diseases. The European Bank for Induced Pluripotent Stem Cells (EBiSC) was established to provide researchers across academia and the pharmaceutical industry with disease...
Funding Programme
Start Date
End Date
Total Funding
€ 34 327 858
European Countries Involved
 
Acknowledgement
Alzheimer Europe's database on research projects was developed as part of the 2020 Work Plan which received funding under an operating grant from the European Union’s Health Programme (2014–2020).